ArticleAntimicrobial agents and chemotherapy2021
Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen.
Open access · greenAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Urosepsis by multidrug-resistantmBio · 2026Article
- Antifungal potential of naphthoquinone derivatives: screening of shikonin-based compounds and mechanistic insights into 5,8-dihydroxy-1,4-naphthoquinone againstMicrobiology spectrum · 2026Article
- Review
- Mechanistic insights into antifungal potential of Alexidine dihydrochloride and hexachlorophene in Candida albicans: a drug repurposing approach.Archives of microbiology · 2024Article
- The Potential of Dutasteride for Treating Multidrug-ResistantPharmaceutics · 2024Article
- Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination.Antimicrobial agents and chemotherapy · 2024Article
- Discovery of a new chemical scaffold for the treatment of superbugEmerging microbes & infections · 2023Article
- Broad susceptibility ofmBio · 2023Article
- Antifungal Development and the Urgency of Minimizing the Impact of Fungal Diseases on Public Health.ACS bio & med chem Au · 2023Review
- Agrochemical Lessons for Infectious Disease Research: New Resistance Breaking Antifungal Hits againstACS medicinal chemistry letters · 2023Article
- Small molecules for combating multidrug-resistant superbugActa pharmaceutica Sinica. B · 2022Review
- Initial Results of the International Efforts in Screening New Agents againstJournal of fungi (Basel, Switzerland) · 2022Article
- Emerging and future strategies in the management of recalcitrant Candida auris.Medical mycology · 2022Review
- Article
- Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Flucytosine and its clinical usage.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Yu-Shan ChengNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.
Jose Santinni RomaLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Min ShenNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.
Caroline Mota FernandesDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Patricia S TsangLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
He Eun ForbesLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Helena BoshoffLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Cristina LazzariniDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.
Maurizio Del PoetaDepartment of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA.ORCID 0000-0001-8418-3120
Wei ZhengNational Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA wzheng@mail.nih.gov williamsonpr@mail.nih.gov.ORCID 0000-0003-1034-0757
Peter R WilliamsonLaboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA wzheng@mail.nih.gov williamsonpr@mail.nih.gov.
National Institutes of Health · USStony Brook University · USNorthport VA Medical Center · US
Funding
Drug Repurposing Screening for Rare and Neglected DiseasesZIATR000018 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI ZHENG, WEI · 2015 to 2025
$24.6MMolecular Pathobiology of Cryptococcus neoformansZIAAI001123 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WILLIAMSON, PETER · 2010 to 2025
$10.4MTranslational Research: Host-Pathogen Interactions in Patient Fungal DiseasesZIAAI001124 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WILLIAMSON, PETER · 2010 to 2025
$8.8MNew antifungals targeting the synthesis of fungal sphingolipidsR01AI116420 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI Maurizio Del Poeta · 2016 to 2026
$7.6MLipid-mediated fungal pathogenesisR01AI125770 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2016 to 2025
$6.2MSphingosine-1-phosphate and cryptococcosisR01AI136934 · NIAID · STATE UNIVERSITY NEW YORK STONY BROOK · PI DEL POETA, MAURIZIO · 2018 to 2022
$2.5MRole of host spingolipids against fungal infectionsI01BX002624 · VA · NORTHPORT VA MEDICAL CENTER · PI Maurizio Del Poeta · 2016 to 2026
–BLRD Research Career Scientist Award ApplicationIK6BX005386 · VA · NORTHPORT VA MEDICAL CENTER · PI DEL POETA, MAURIZIO · 2021 to 2025
–BLRD VA I01 BX002624BLRD VA IK6 BX005386NIAID NIH HHS R01 AI116420NIAID NIH HHS R01 AI125770NIAID NIH HHS R01 AI136934
Abstract
PubMed holds no abstract for this paper.
Indexed as
CandidaPharmaceutical PreparationsAntifungal AgentsDrug RepositioningMicrobial Sensitivity TestsAntifungal AgentsPharmaceutical PreparationsCandida aurisdrug combination therapydrug repurposingmultidrug resistance
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.